drugset / Trial / NCT06113640

Montelukast in Parkinson Disease

NCT06113640

Phase 2/3 Recruiting 60 enrolled Mostafa Bahaa
RandomizedParallel-groupDouble-blindTreatment

Summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease (AD). Clinical manifestations of PD can vary, but a formal diagnosis relies on the presence of bradykinesia with rigidity and/or rest tremor according to Movement Disorder Society (MDS) criteria for PD. Non-motor symptoms, such as hyposmia, constipation, depression, and rapid eye movement (REM) sleep behavior disorder, are common and can in many cases manifest before classical motor symptoms. In later years, more emphasis has been put on non-motor symptoms, especially in the early stages of PD and which is evident in the proposed prodromal PD criterion by MDS.

Timeline

Start
2023-11-05
Primary completion
2026-11-20
Completion
2026-12-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Montelukast Other / unclassified 10 mg
Comparator Carbidopa Unknown 25 mg
Comparator Levodopa Small molecule 250 mg

Indications